# Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma

> **NCT02424045** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 30 (actual)

## Conditions studied

- T-cell Lymphoma

## Interventions

- **DRUG:** BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)

## Key facts

- **NCT ID:** NCT02424045
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02424045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02424045, "Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02424045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*